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Brief Clinical ReportsII (Thoratec, Pleasanton, Calif) axial flow pumps have sus-
tained patients for 4 years. Given the reservations about sur-
vival advantage and economic viability of cardiac
transplantation in United Network for Organ Sharing status II
patients, properly structured clinical trials to compare LVADs
with transplantation or continuedmedical therapy are indicated
and probably overdue.5 Indeed, for thosewhowish to avoid the
side effects of immunosuppression, a rotary blood pumpmight
provide a realistic alternative to a donor heart.
In the meantime, rotary blood pumps can offer symptom-
atic relief for many patients with heart failure who will never
reach a transplant waiting list.From Cardiopulmonary Transplantation, University of Pittsburgh Medical Center,
Pittsburgh, Pa.
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Christian Bermudez, MD, Brack G. Hattler, MD, Bruce Johnson, MD, Maria Crespo, MD,
Joseph Pilewski, MD, and Yoshiya Toyoda, MD, Pittsburgh, PaAdvanced recipient age continues to be used as an exclusion
criterion for lung transplantation.1 However, given the
changing age demographics in most developed countries,
redefinition of the appropriate recipient age limit for lung
transplantation is needed because it has become an estab-
lished therapeutic option with acceptable mortality for end-
stage lung diseases. Given those conditions, we recently have
expanded our criteria for both recipients and donors in lung
transplantation.2 We present the case of an 81-year-old man
with idiopathic pulmonary fibrosis (IPF) who is the oldest
known successful lung transplant recipient reported.CLINICAL SUMMARY
An 81-year-old man who had been an active businessman
and enjoyed golf after retirementwas given a diagnosis of IPF
in 2005 and treated with oral steroids and azathioprine. He
became oxygen dependent and severely limited in activities
of daily living (from Fletcher Hugh–Jones criteria 4 to 5). Af-
ter failing all other therapeutic initiatives, he was referred to
one major medical center in the United States for lung trans-
plantation evaluation. However, because of his advancedage, he was declined and referred to our center to re-evaluate
his lung transplantation candidacy. Although the patient had
a past history of prostate cancer in 1992, there was no evi-
dence of recurrence during the 5 years before our re-evalua-
tion, and he was deemed a suitable candidate based on our
multidisciplinary transplant selection committee criteria. At
the time of listing, he had severely restrictive pulmonary
function, with a forced vital capacity of 1.59 L (41% of pre-
dicted value), a forced expiratory volume in 1 second of 1.35
L (56% of predicted value), and a diffusion capacity for car-
bon monoxide of 3.88 L/min/kpa (23% of predicted value).
Furthermore, blood gas on room air showed a PO2 of 48 mm
Hg and a PCO2 of 36 mmHg. The 6-minute walk results were
770 feet on 6 L of oxygen through a nasal cannula with desa-
turation to 85%. Cardiac catheterization showed a systolic
pulmonary artery pressure of 43 mm Hg, a transpulmonary
gradient of 15 mm Hg, and mild coronary artery disease.
A chest radiograph on admission is shown in Figure 1, A.
In April 2007, a 51-year-old man with no smoking history
became available as a donor. The donor was 66 inches in
height, whereas the recipient was 68 inches. We performed
a left single-lung transplantation without cardiopulmonary
bypass, during which the allograft ischemic time was 245
minutes. Immunosuppressive therapy consisted of intrave-
nous alemtuzumab (Campath-1H; Genzyme Corporation,
Cambridge, Mass) as induction therapy, with oral tacrolimus,
mycophenolate mofetil, and prednisone administered postop-
eratively. Recovery from the procedure was uneventful. He
was extubated on postoperative day 1 and was discharged
from the hospital 21 days after transplantation without supple-
mental oxygen. At present, 1 year after transplantation, therdiovascular Surgery c Volume 139, Number 3 e47
FIGURE 1. Chest roentgenogram on admission (A) and 6 months after left
single-lung transplantation (B).
Brief Clinical Reportspatient leads an independent and active lifestyle and performs
normal activities of daily living without dyspnea or the need
for oxygen. Recent pulmonary function tests showed a forced
vital capacity of 2.43 L (64% of predicted value) and a forced
expiratory volume in 1 second of 2.05 L (86% of predicted
value).A chest radiograph6months after left single lung trans-
plantation is shown in Figure 1, B.
DISCUSSION
We report a case of successful single-lung transplantation
in an 81-year-old man with respiratory failure caused by IPF.
Our reports demonstrated that an acceptable outcome is pos-
sible after single-lung transplantation for an octogenarian,
despite advanced age. Over the past 2 decades, lung trans-
plantation has become an established life-saving therapy
for patients with end-stage lung diseases, and increasing
numbers of transplantations are being performed throughoute48 The Journal of Thoracic and Cardiovascular Surgthe world. IPF is the second most common indication for
lung transplantation in the United States, and most of those
patients are older than 50 years.3
To date, lung transplantation remains the only interven-
tion proved to confer a survival benefit over the best medical
therapy in selected patients with IPF.4 However, if a strict
age limit of 60 or 65 years were used for lung transplanta-
tion, a quarter of the population in North America and Eu-
rope would be categorically denied this therapeutic option
because of changing age demographics. Several reports
have already demonstrated that lung transplantation can be
performed with very acceptable immediate and long-term re-
sults in appropriately selected patients who are 60 years of
age and older.5 In our institution approximately 30% of
the recipients since 2004 were older than 60 years, and their
overall outcomes have not been compromised compared
with those of patients selected less aggressively before 2004.
Multiple risk factors predictive of higher mortality after
lung transplantation, such as prior sternotomy or thoracot-
omy, body mass index of greater than 25, increased bilirubin
or creatinine levels, and increased pulmonary artery pressure,
should be considered in combination when evaluating older
recipients for a potential lung transplantation.3 However, we
believe that age alone should not exclude patients from con-
sideration of lung transplantation. In this case lung transplan-
tation saved an 81-year-old patient from his life-threatening
condition and has successfully provided him with quality-
of-life improvements for longer than 1 year.
A number of complicated issues remain debatable, includ-
ing ethical concerns, regarding this important topic, which
we intend to investigate more thoroughly in our next report
with a larger number of elderly cases of higher age. We con-
sider that additional studies of the effect of advanced age
along with other individual risk factors on outcome after
lung transplantation will improve preoperative risk predic-
tion and promote improvement of selection criteria for
lung transplant recipients.References
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